Clinical Trial Update: Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks

View source ↗

Summary

Postmarketing study evaluating the relationship between ORTHO EVRA and risks of venous thromboembolism, stroke, and myocardial infarction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• Stroke
• Venous Thromboembolism

Drugs mentioned

• ORTHO EVRA (ethinyl estradiol / norelgestromin)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Contraception, Female Contraception | Status: COMPLETED